In a recent vote, New York regulators agreed to allow medical cannabis operators to apply for adult-use retail licenses.
New York regulators have voted in September 2023 to allow state medical cannabis operators to be able to apply for adult-use retail licenses. This poses a problem though for small businesses because multistate operators (MSOs) would be able to take part. Years ago, MSOs snatched a majority of New York’s 10 “registered organization” permits (1).
Resolutions that were approved by the Office of Cannabis Management will begin taking applications looking for a microbusiness or retail license, between October 4 – December 23, 2023. Registered organizations will also be accepted but during a unspecified window that will be “set by the Office” (1). This measure was a part of a separate resolution.
“Today marks a pivotal step toward expanding and sustaining the state’s medical program and creation of an economically viable and equitable adult-use cannabis industry in New York,” Barry Carmody, a spokesperson for the New York Medical Cannabis Industry Association (NYMCIA), said after a Cannabis Control Board meeting in Albany (1).
Eight of the current medical cannabis licenses are represented by the NYMCIA. This includes major MSOs (1). For example, Columbia Care and Acreage Holdings, who are based in New York. As well as, Green Thumb Industries and Cresco Labs who are headquartered in Chicago and lastly, Curaleaf Holdings, who originates from Massachusetts.
According to MJBiz, the Office of Cannabis Management’s vote can be defined as (1):
This vote took place not long after CEOs from four MSO operators asked New York Governor Kathy Hochul to permit them to enter the state’s adult-use market “without delay,” (1).
Small cannabis businesses have not taken this resolution well as they say it will harm their businesses. “Today’s Cannabis Control Board meeting opened the door for big cannabis to come in and compete with New York-based businesses,” the Cannabis Association of New York (CANY), which represents small and state-based businesses, said in a statement (1).
However, CANY enclosed demands to New York Regulators (1):
New York is undergoing a transformation within their state’s cannabis industry. With the permittance of MSOs now being allowed to enter the market, hopefully small businesses throughout New York State (NYS), such as Strain Stars, the first dispensary to open on Long Island (2) can succeed in the cannabis industry as well.
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.